ALOX5 and atherosclerosis: LTB4, the downstream metabolite of 5-LOX, increases the mRNA expression of IL-6 and MCP-1 via BLT1 and BLT2, G protein-coupled receptors of leukotrienes, via a NF-κB-dependent mechanism in atherosclerosis [38].